CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) saw a significant growth in short interest in August. As of August 31st, there was short interest totalling 125,600 shares, a growth of 5.3% from the August 15th total of 119,300 shares. Based on an average daily volume of 65,200 shares, the short-interest ratio is presently 1.9 days. Approximately 2.7% of the shares of the stock are sold short.
Analyst Upgrades and Downgrades
Separately, Benchmark reissued a “speculative buy” rating and set a $5.00 price objective on shares of CytoMed Therapeutics in a research note on Tuesday, June 11th.
Read Our Latest Research Report on CytoMed Therapeutics
CytoMed Therapeutics Stock Down 1.6 %
CytoMed Therapeutics Company Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Further Reading
- Five stocks we like better than CytoMed Therapeutics
- Using the MarketBeat Dividend Tax Calculator
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Stock Market Sectors: What Are They and How Many Are There?
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
- What Are the FAANG Stocks and Are They Good Investments?
- Is Alphabet a Long-Term Buying Opportunity After Recent Declines?
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.